Abstract
Efficacy and safety of bortezomib-containing induction chemotherapy for autologous stem cell transplantation-eligible Japanese multiple myeloma patients—A phase 2 multicenter trial—
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have